Role of P-glycoprotein in region-specific gastrointestinal absorption of talinolol in rats

Drug Metabolism and Disposition

Volumn 38, Issue 9, 2010, Pages 1560-1566

  Kagan, Leonid ^a   Dreifinger, Tali ^b   Mager, Donald E ^a   Hoffman, Amnon ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; GLYCOPROTEIN P; TALINOLOL; VERAPAMIL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COLON; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TRANSPORT; EXPERIMENTAL MODEL; GASTROINTESTINAL ABSORPTION; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; RAT; STEADY STATE; STOMACH; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; INTESTINAL ABSORPTION; MALE; P-GLYCOPROTEINS; PROPANOLAMINES; RATS; RATS, WISTAR;

RATTUS;

EID: 77956003276     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033019     Document Type: Article

References (40)

1. Augustijns P and Mols R (2004) HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. J Pharm Biomed Anal 34:971-978.
2. Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, Schrenk D, and Lennernäs H (2007) Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 4:252-257.
3. Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, Lennernas H, Zhong Y, Amidon GL, Yu LX, et al. (2006) Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 23:1675-1686.
4. Chiou WL and Barve A (1998) Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15:1792-1795.
5. Dahan A, Sabit H, and Amidon GL (2009) Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of P-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos 37:2028-2036.
6. Fagerholm U, Johansson M, and Lennernäs H (1996) Comparison between permeability coefficients in rat and human jejunum. Pharm Res 13:1336-1342. (Pubitemid 26344978)
7. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84:265-269.
8. Fricker G, Drewe J, Huwyler J, Gutmann H, and Beglinger C (1996) Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 118:1841-1847.
9. Gibaldi M and Perrier D (1982) Pharmacokinetics, Marcel Dekker, New York.
10. Gramatté T, Oertel R, Terhaag B, and Kirch W (1996) Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther 59:541-549. (Pubitemid 26191376)
11. Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E, and Friedman M (2004) Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm 277:141-153.
12. Kagan L and Hoffman A (2008a) Selection of drug candidates for gastroretentive dosage forms: pharmacokinetics following continuous intragastric mode of administration in a rat model. Eur J Pharm Biopharm 69:238-246.
13. Kagan L and Hoffman A (2008b) Systems for region selective drug delivery in the gastrointestinal tract: biopharmaceutical considerations. Expert Opin Drug Deliv 5:681-692.
14. Kivistö KT, Niemi M, and Fromm MF (2004) Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 18:621-626. (Pubitemid 39564261)
15. Lin JH, Chiba M, and Baillie TA (1999) Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 51:135-158.
16. Maki N, Hafkemeyer P, and Dey S (2003) Allosteric modulation of human P-glycoprotein. Inhibition of transport by preventing substrate translocation and dissociation. J Biol Chem 278:18132-18139.
17. Mouly S and Paine MF (2003) P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 20:1595-1599. (Pubitemid 37268274)
18. Mummaneni V and Dressman JB (1994) Intestinal uptake of cimetidine and ranitidine in rats. Pharm Res 11:1599-1604.
19. Nakayama A, Saitoh H, Oda M, Takada M, and Aungst BJ (2000) Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system. Eur J Pharm Sci 11:317-324.
20. Raub TJ (2006) P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 3:3-25.
21. Rojanasakul Y, Wang LY, Bhat M, Glover DD, Malanga CJ, and Ma JK (1992) The transport barrier of epithelia: a comparative study on membrane permeability and charge selectivity in the rabbit. Pharm Res 9:1029-1034.
22. Rouge N, Buri P, and Doelker E (1996) Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm 136:117-139.
23. Sawamoto T, Haruta S, Kurosaki Y, Higaki K, and Kimura T (1997) Prediction of the plasma concentration profiles of orally administered drugs in rats on the basis of gastrointestinal transit kinetics and absorbability. J Pharm Pharmacol 49:450-457. (Pubitemid 27207703)
24. Schwarz UI, Dresser GK, Oertel R, and Kim RB (2001) Talinolol-verapamil interaction is not solely due to P-glycoprotein inhibition. Clin Pharmacol Ther 69:PIII-86.
25. Schwarz UI, Gramatté T, Krappweis J, Berndt A, Oertel R, von Richter O, and Kirch W (1999) Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans. Clin Pharmacol Ther 65:283-290.
26. Sharom F (2007) Multidrug resistance protein: P-glycoprotein, in Drug Transporters. Molecular Characterization and Role in Drug Disposition (You G and Morris M eds) pp 223-262, John Wiley & Sons, Inc., Hoboken, NJ.
27. Shirasaka Y, Kuraoka E, Spahn-Langguth H, Nakanishi T, Langguth P, and Tamai I (2010) Species difference in the effect of grapefruit juice on intestinal absorption of talinolol between human and rat. J Pharmacol Exp Ther 332:181-189.
28. 1-adrenoceptor antagonist talinolol mediated by P-glycoprotein and organic anion transporting polypeptide (Oatp). Pharm Res 26:560-567.
29. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, and Langguth P (1998) P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24.
30. Streubel A, Siepmann J, and Bodmeier R (2006) Gastroretentive drug delivery systems. Expert Opin Drug Deliv 3:217-233.
31. Tian R, Koyabu N, Takanaga H, Matsuo H, Ohtani H, and Sawada Y (2002) Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 19:802-809. (Pubitemid 34686739)
32. 1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 16:403-414.
33. Tronde A, Nordén B, Marchner H, Wendel AK, Lennernäs H, and Bengtsson UH (2003) Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. J Pharm Sci 92:1216-1233.
34. Tubic M, Wagner D, Spahn-Langguth H, Bolger MB, and Langguth P (2006a) In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm Res 23:1712-1720.
35. Tubic M, Wagner D, Spahn-Langguth H, Weiler C, Wanitschke R, Böcher WO, and Langguth P (2006b) Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans. Eur J Pharm Sci 29:231-239.
36. Watanabe T, Kusuhara H, Maeda K, Shitara Y, and Sugiyama Y (2009) Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J Pharmacol Exp Ther 328:652-662.
37. Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, and Siegmund W (2005) The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm Res 22:728-735.
38. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rösch W, and Langguth P (1996) Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13:514-522. (Pubitemid 26119052)
39. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, and Takano M (1999) Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289:149-155.
40. Zhao YH, Abraham MH, Le J, Hersey A, Luscombe CN, Beck G, Sherborne B, and Cooper I (2003) Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem 38:233-243.